Department of Surgery »  Faculty »  General Surgery »  Carlos U. Corvera, M.D.

Carlos U. Corvera, M.D.

Professor of Surgery
Chief, Hepatobiliary and Pancreas Surgery
Division of General Surgery
Maurice Galante, MD Distinguished Professor in Hepatobiliary Surgery

Contact Information

Academic Office
1600 Divisadero Street
Box 1932 | University of California, San Francisco
San Francisco, CA 94143-1932
Voice (415) 353-9294
Fax (415) 353-9695
Carlos.Corvera@ucsf.edu
Open Popup
  • 1983-86 University of California, Davis, CA  B.S. Biochemistry College of Agricultural and Environmental Science
  • 1989-93 University of California, San Diego Medical School.  M.D.  La Jolla, CA
  • 1993-1995,University of California, San Francisco, Intern and Resident,Surgery
  • 1995-1998 University of California, San Francisco, Research Fellow Surgery, Division of Gastrointestinal Surgery
  • 998-2000,University of California, San Francisco, Senior Resident Surgery
  • 2000-2001,University of California, San Francisco, Chief Resident Surgery
  • 2001-2002, Memorial Sloan-Kettering Cancer Center, Fellow ,Surgical Oncology, New York,  New York
  • 2002-2003, Memorial Sloan-Kettering Cancer Center, Fellow, Hepatobiliary Surgery, New York,  New York
  • American Board of Surgery
  • Hepatobiliary and Pancreas Surgery Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery at the San Francisco VA
  • Proteases and Proteinase Activated Receptors in the Biliary Tract

Carlos Corvera, M.D. is Associate Professor of Surgery and Chief of Hepatobiliary and Pancreas Surgery at UCSF.  A trained surgical oncologist, Dr. Corvera has extensive experience in the treatment of benign and malignant hepatobiliary disease including hepatocellular carcinoma (primary liver cancer), liver metastases, and cancers of the stomach, gall bladder, bile ducts, and pancreas. Additionally, Dr. Corvera performs surgery for  melanoma and  soft tissue sarcomas. Dr. Corvera specializes in complex and intricate cancer surgeries, including minimally invasive liver resections that greatly minimize post-operative pain and speed recovery. Dr. Corvera, who performs a high volume of such procedures, is also a pioneer and innovator of surgical techniques in the field.

Dr. Corvera graduated from the University of California San Diego School of Medicine. He completed his general surgery residency at UCSF, and prestigious fellowships in surgical oncology and hepatobiliary surgery at Memorial Sloan-Kettering Cancer Center. 

In May 2013, Dr. Corvera was installed as the President of the UCSF Naffziger Surgical Society, the alumni society for the UCSF Department of Surgery. Dedicated to surgical excellence, the society has long served as a forum fostering collaboration between surgeons and promoting surgical advances through its educational forums.

Dr. Corvera's scientific research interest is focused on understanding the mechanisms of biliary tract fibrosis and inflammation.  More specifically, he is interested in studying the clinical consequences of biliary fibrosis-- mainly cholestatisis. Cholestasis is characterized by impaired bile flow causing a high concentration of bile acids in the liver and the circulation.  Prolonged exposure to bile acids in the liver can progress to end-stage liver disease and cirrhosis. In the gastrointestinal tract, the absence of bile flow causes profound local and systemic metabolic disturbances. Dr.Corvera is actively investigating the role of a novel cell surface receptor specific for bile acids that may play a critical role in normal and disease states.

Most recent publications from a total of 43
  1. Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 2016 Jun 2; 18(6):809-16. View in PubMed
  2. Qadan M, Garden OJ, Corvera CU, Visser BC. Management of Postoperative Hepatic Failure. J Am Coll Surg. 2016 Feb; 222(2):195-208. View in PubMed
  3. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21. View in PubMed
  4. Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, McIntyre P, Bron R, Wilson YM, Krappitz M, Haerteis S, Korbmacher C, Steinhoff MS, Nassini R, Materazzi S, Geppetti P, Corvera CU, Bunnett NW. The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice. Gastroenterology. 2014 Dec; 147(6):1417-28. View in PubMed
  5. Leung U, Pandit-Taskar N, Corvera CU, D'Angelica MI, Allen PJ, Kingham TP, DeMatteo RP, Jarnagin WR, Fong Y. Impact of pre-operative positron emission tomography in gallbladder cancer. HPB (Oxford). 2014 Nov; 16(11):1023-30. View in PubMed
  6. Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, Corvera CU, Monto A. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014 Aug; 16(8):758-67. View in PubMed
  7. Jensen DD, Godfrey CB, Niklas C, Canals M, Kocan M, Poole DP, Murphy JE, Alemi F, Cottrell GS, Korbmacher C, Lambert NA, Bunnett NW, Corvera CU. The bile acid receptor TGR5 does not interact with ß-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem. 2013 Aug 9; 288(32):22942-60. View in PubMed
  8. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, Cevikbas F, Steinhoff M, Nassini R, Materazzi S, Guerrero-Alba R, Valdez-Morales E, Cottrell GS, Schoonjans K, Geppetti P, Vanner SJ, Bunnett NW, Corvera CU. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013 Apr 1; 123(4):1513-30. View in PubMed
  9. Rajagopal S, Kumar DP, Mahavadi S, Bhattacharya S, Zhou R, Corvera CU, Bunnett NW, Grider JR, Murthy KS. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac- and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am J Physiol Gastrointest Liver Physiol. 2013 Mar 1; 304(5):G527-35. View in PubMed
  10. Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013 Jan; 144(1):145-54. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Carlos U. Corvera, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X